Sandbox Reserved 433
From Proteopedia
(Difference between revisions)
| Line 11: | Line 11: | ||
This is a sample scene created with SAT to <scene name="/12/3456/Sample/1">color</scene> by Group, and another to make <scene name="/12/3456/Sample/2">a transparent representation</scene> of the protein. | This is a sample scene created with SAT to <scene name="/12/3456/Sample/1">color</scene> by Group, and another to make <scene name="/12/3456/Sample/2">a transparent representation</scene> of the protein. | ||
| - | GSK-3 is a serine/threonine protein kinase which regulates the addition of phosphate molecules onto serineand threonine amino acid residues. Serine/threonine protein kinases are responsible for phosphorylating the serine/threonine kinase receptors which play a role in the regulation of cell proliferation, programmed cell death (apoptosis), cell differentiation, and embryonic development. | + | GSK-3 is a serine/threonine protein kinase which regulates the addition of phosphate molecules onto serineand threonine amino acid residues. Serine/threonine protein kinases are responsible for phosphorylating the serine/threonine kinase receptors which play a role in the regulation of cell proliferation, programmed cell death (apoptosis), cell differentiation, and embryonic development <ref>PMID: 16912193</ref>. GSK-3 has two isoforms, GSK-3 beta and GSK-3 alpha. GSK-3 beta is more involved in energy metabolism, neuronal cell development, and body pattern formation, while GSK-3 alpha has more function with WNT signaling pathways. GSK-3 beta is found in most mammals, all with similar structure and function. In experiments when GSK-3 beta was perturbed in mice, embryonic lethality during mid-gestation was demonstrated. |
| - | GSK-3 beta has been shown to negatively regulates TGF-beta1 and Angiotensin II-mediated cellular activity through interaction with Smad3. GSK-3 beta directly interacts with Smad3, preventing its movement into the nucleolus, which don't allow it to perform cell death. This forces Angiotensin II apoptosis in cardiac myocytes. | + | GSK-3 beta has been shown to negatively regulates TGF-beta1 and Angiotensin II-mediated cellular activity through interaction with Smad3. GSK-3 beta directly interacts with Smad3, preventing its movement into the nucleolus, which don't allow it to perform cell death. This forces Angiotensin II apoptosis in cardiac myocytes<ref>PMID: 14529625</ref>. Other enzymes that this kinase interacts with are: AKAP11, AXIN1, AXIN2, AR, CTNNB1, DNM1L, MACF1 MUC1, SMAD3[ NOTCH1,NOTCH2, P53, PRKAR2A, SGK3, and TSC2<ref>PMID: 20599907</ref>. Recent research in regards to GSK-3 includes type II diabetes , Alzheimer's Disease, inflammation, cancer, and bipolar disorder. This page demonstrates a GSK-3 complex with a Staurosporine inhibitor. |
==Overall Structure== | ==Overall Structure== | ||
| - | Glycogen Synthase Kinase-3 (GSK-3) is a serine/threonine kinase monomer and has an overall structure that is characteristic of the apoenzyme. It has two phosphorylation sites that are involved in catalysis. One of these sites is Ser9, which is the phosphorylation site for AKT, resulting in the inactivation of GSK-3beta. The second phosphorylation site is Tyr216, located on the activation loop (shown in green), and is responsible for the increase in catalytic activity. GSK-3beta has the characteristic two-domain kinase fold, containing a N-terminal beta-strand domain (light blue, residues 25-138) and a C-terminal alpha-helical domain (red, residues 139-343). There is an interface between the alpha and beta domains, at which the ATP-binding site is located, encircled by the hinge and the glycine-rich loop. The activation loop (purple) runs along the surface of the substrate-binding groove. There are 39 residues in the C-terminus end that are outside the main kinase fold. These residues form a small domain that closely packs next to the alpha-helical domain. The beta-strand domain is formed by seven beta-strands that run in an antiparallel formation. Strands 2-6 form a beta-barrel, through which a short alpha helix (yellow, residues 96-102) aligns against the beta-barrel. Two of this short helix’s residues play important roles in the catalytic action of GSK-3beta. A salt bridge, which is important in binding interactions, is positioned in the active site between Glu97 and Lys85 | + | Glycogen Synthase Kinase-3 (GSK-3) is a serine/threonine kinase monomer and has an overall structure that is characteristic of the apoenzyme. It has two phosphorylation sites that are involved in catalysis. One of these sites is Ser9, which is the phosphorylation site for AKT, resulting in the inactivation of GSK-3beta. The second phosphorylation site is Tyr216, located on the activation loop (shown in green), and is responsible for the increase in catalytic activity. GSK-3beta has the characteristic two-domain kinase fold, containing a N-terminal beta-strand domain (light blue, residues 25-138) and a C-terminal alpha-helical domain (red, residues 139-343). There is an interface between the alpha and beta domains, at which the ATP-binding site is located, encircled by the hinge and the glycine-rich loop. The activation loop (purple) runs along the surface of the substrate-binding groove. There are 39 residues in the C-terminus end that are outside the main kinase fold. These residues form a small domain that closely packs next to the alpha-helical domain. The beta-strand domain is formed by seven beta-strands that run in an antiparallel formation. Strands 2-6 form a beta-barrel, through which a short alpha helix (yellow, residues 96-102) aligns against the beta-barrel. Two of this short helix’s residues play important roles in the catalytic action of GSK-3beta. A salt bridge, which is important in binding interactions, is positioned in the active site between Glu97 and Lys85<ref>PMID: 11427888</ref>. |
<scene name='48/483890/Overall_structure_of_gsk-3beta/3'>Green Scene for Overall Structure</scene> | <scene name='48/483890/Overall_structure_of_gsk-3beta/3'>Green Scene for Overall Structure</scene> | ||
| Line 32: | Line 32: | ||
Besides direct H-bond, the water-mediated polar interactions are observed between the <span style="color:red">'''carbonyl oxygen'''</span> of Gln 185 and <span style="color:blue">'''N<sup>4</sup> (nitrogen)'''</span> of the glycosidic ring. | Besides direct H-bond, the water-mediated polar interactions are observed between the <span style="color:red">'''carbonyl oxygen'''</span> of Gln 185 and <span style="color:blue">'''N<sup>4</sup> (nitrogen)'''</span> of the glycosidic ring. | ||
| - | The typical hydrogen bond (H-bond) is categorized to be between 2.2 and 4.0 Å | + | The typical hydrogen bond (H-bond) is categorized to be between 2.2 and 4.0 Å <ref name="rasmol">Jeffrey, George A. An introduction to hydrogen bonding; Oxford University Press: Oxford, 1997</ref>. |
| - | Since many pdb files lack hydrogen atoms, a significant H-bond can be considered when donor-acceptor distance are probably 3.5 Å | + | Since many pdb files lack hydrogen atoms, a significant H-bond can be considered when donor-acceptor distance are probably 3.5 Å<ref name="rasmol">. |
| - | However, the length between between Gln 185 and Strauroporine is 4.47 Å which surpasses typical H-bond distance; therefore, it forms a water mediated polar interaction between these atoms instead of direct H-bond | + | However, the length between between Gln 185 and Strauroporine is 4.47 Å which surpasses typical H-bond distance; therefore, it forms a water mediated polar interaction between these atoms instead of direct H-bond |
This is a unique interaction to the GSK-3β and staurosporine complex, since other protein kinase (e.g. CDK2, Chk1, LCK, PKA) -staurosporine complexes show direct H-bond interaction between two moieties. | This is a unique interaction to the GSK-3β and staurosporine complex, since other protein kinase (e.g. CDK2, Chk1, LCK, PKA) -staurosporine complexes show direct H-bond interaction between two moieties. | ||
| - | There is a significant number of <scene name='48/483890/Additional_feature_v4/2'>hydrophobic interaction</scene> in the GSK-3β and staurosporine complex; to be more specific, this complex buries 891 Å<sup>2</sup> surface area | + | There is a significant number of <scene name='48/483890/Additional_feature_v4/2'>hydrophobic interaction</scene> in the GSK-3β and staurosporine complex; to be more specific, this complex buries 891 Å<sup>2</sup> surface area. The <span style="color:pink">'''hydrophobic residues'''</span> significantly interact with the fuzed carbazole moiety of saurosporine. |
==Quiz Question 1== | ==Quiz Question 1== | ||
| - | GSK-3 beta has various inhibiters; one example is AMP-PMP. These inhibitors bind to the N-terminus of the ligand on the GSK-3 beta complex, a result of the classical binding mechanism for a protein kinase. However, in the case of staurosporine (another inhibitor), it is unable to classically bind to the N-terminus of the ligand on the GSK-3 beta complex. This is because, in a GSK-3 beta complex with staurosporine, the ligand in question has an incompatible angle at the N-terminus, thus failing to undergo classical binding. | + | GSK-3 beta has various inhibiters; one example is AMP-PMP. These inhibitors bind to the N-terminus of the ligand on the GSK-3 beta complex, a result of the classical binding mechanism for a protein kinase. However, in the case of staurosporine (another inhibitor), it is unable to classically bind to the N-terminus of the ligand on the GSK-3 beta complex. This is because, in a GSK-3 beta complex with staurosporine, the ligand in question has an incompatible angle at the N-terminus, thus failing to undergo classical binding<ref name="rasmol">. |
What type of bonding does GSK-3 beta exhibit with staurosporine, and which of its residues form this type of bond? A green screen of the complex as well as a lewis structure of the staurosporine molecule are found below, if needed. | What type of bonding does GSK-3 beta exhibit with staurosporine, and which of its residues form this type of bond? A green screen of the complex as well as a lewis structure of the staurosporine molecule are found below, if needed. | ||
| Line 90: | Line 90: | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| - | (1) Bertrand, J. A., Thieffine, S., Vulpetti, A., et al. GSK-3 Beta complexed with Staurosporine 2003 | ||
| - | (2) Capra, M , Nuciforo, P Confalonieri, S Quarto, S Bianchi, M Nebuloni, M Boldorini, R Pallotti, F. Frequent Alterations in the Expression of Serine/Threonine Kinases in Human Cancers 2006 | ||
| - | |||
| - | (3) Hua F1, Zhou J, Liu J, Zhu C, Cui B, Lin H, Liu Y, Jin W, Yang H, Hu Z. Glycogen synthase kinase-3beta negatively regulates TGF-beta1 and Angiotensin II-mediated cellular activity through interaction with Smad3. 2010 | ||
| - | (4) Haar, E., Coll, J. T., Austen, D. A., Hsiao, H-M., Swenson, L., Jain, J. Structure of GSK3B reveals a primed phosphorylation mechanism. Vertex Pharmaceuticals Incoprporated, Cambridge MA. Nature Publishing Group, Vol 8 No 7. July 2001. | ||
Revision as of 23:44, 5 April 2015
| This Sandbox is Reserved from January 19, 2016, through August 31, 2016 for use for Proteopedia Team Projects by the class Chemistry 423 Biochemistry for Chemists taught by Lynmarie K Thompson at University of Massachusetts Amherst, USA. This reservation includes Sandbox Reserved 425 through Sandbox Reserved 439. |
| |||||||||||
